Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

09.17

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Read More
09.14

Zynerba Pharmaceuticals Provides Update on Recent Milestones

Read More
09.10

Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

Read More
08.10

Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights

Read More